|
1
|
Skeldon SC and Goldenberg SL: Bladder
cancer: A portal into men's health. Urol Oncol. 33:40–44. 2015.
View Article : Google Scholar
|
|
2
|
Bellmunt J, Orsola A, Leow JJ, Wiegel T
and De Santis M: Bladder cancer: ESMO Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3):
iii40–iii48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A;
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pang KH and Catto JWF: Bladder cancer.
Surgery. 31:523–529. 2013.
|
|
5
|
Svatek RS, Hollenbeck BK, Holmäng S, Lee
R, Kim SP, Stenzl A and Lotan Y: The economics of bladder cancer:
costs and considerations of caring for this disease. Eur Urol.
66:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sio TT, Ko J, Gudena VK, Verma N and
Chaudhary UB: Chemotherapeutic and targeted biological agents for
metastatic bladder cancer: A comprehensive review. Int J Urol.
21:630–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nadal R and Bellmunt J: New treatments for
bladder cancer: When will we make progress? Curr Treat Options
Oncol. 15:99–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li H, Yu G, Shi R, Lang B, Chen X, Xia D,
Xiao H, Guo X, Guan W, Ye Z, et al: Cisplatin-induced epigenetic
activation of miR-34a sensitizes bladder cancer cells to
chemotherapy. Mol Cancer. 13:82014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petrelli F, Coinu A, Cabiddu M, Ghilardi
M, Vavassori I and Barni S: Correlation of pathologic complete
response with survival after neoadjuvant chemotherapy in bladder
cancer treated with cystectomy: A meta-analysis. Eur Urol.
65:350–357. 2014. View Article : Google Scholar
|
|
10
|
Jones PM and George AM: A reciprocating
twin-channel model for ABC transporters. Q Rev Biophys. 47:189–220.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang G and Roth CB: Structure of MsbA
from E. coli: A homolog of the multidrug resistance ATP binding
cassette (ABC) transporters. Science. 293:1793–1800. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anreddy N, Gupta P, Kathawala RJ, Patel A,
Wurpel JN and Chen ZS: Tyrosine kinase inhibitors as reversal
agents for ABC transporter mediated drug resistance. Molecules.
19:13848–13877. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misra S, Ghatak S and Toole BP: Regulation
of MDR1 expression and drug resistance by a positive feedback loop
involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol
Chem. 280:20310–20315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe
S, Mills GB and Unate H: Induction of human MDR1 gene expression by
2-acety-laminofluorene is mediated by effectors of the
phosphoinositide 3-kinase pathway that activate NF-kappaB
signaling. Oncogene. 21:1945–1954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tazzari PL, Cappellini A, Ricci F,
Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L,
McCubrey JA, et al: Multidrug resistance-associated protein 1
expression is under the control of the phosphoinositide 3
kinase/Akt signal transduction network in human acute myelogenous
leukemia blasts. Leukemia. 21:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu XF, Slater A, Wall DM, Kantharidis P,
Parkin JD, Cowman A and Zalcberg JR: Rapid up-regulation of mdr1
expression by anthracyclines in a classical multidrug-resistant
cell line. Br J Cancer. 71:931–936. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schöndorf T, Neumann R, Benz C, Becker M,
Riffelmann M, Göhring UJ, Sartorius J, von König CH, Breidenbach M,
Valter MM, et al: Cisplatin, doxorubicin and paclitaxel induce mdr1
gene transcription in ovarian cancer cell lines. Recent Results
Cancer Res. 161:111–116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Y and Ling XL: Establishment of a
cisplatin-induced multidrug resistance cell line SK-Hep1/DDP. Chin
J Cancer. 29:167–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers. 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He T, Mo A, Zhang K and Liu L: ABCB1/MDR1
gene polymorphism and colorectal cancer risk: A meta-analysis of
case-control studies. Colorectal Dis. 15:12–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holland IB: ABC transporters, mechanisms
and biology: An overview. Essays Biochem. 50:1–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Shawi MK: Catalytic and transport
cycles of ABC exporters. Essays Biochem. 50:63–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koenderink JB, Kavishe RA, Rijpma SR and
Russel FG: The ABCs of multidrug resistance in malaria. Trends
Parasitol. 26:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dean M and Annilo T: Evolution of the
ATP-binding cassette (ABC) transporter superfamily in vertebrates.
Annu Rev Genomics Hum Genet. 6:123–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guan Z, Ding C, Du Y, Zhang K, Zhu JN,
Zhang T, He D, Xu S, Wang X and Fan J: HAF drives the switch of
HIF-1α to HIF-2α by activating the NF-κB pathway, leading to
malignant behavior of T24 bladder cancer cells. Int J Oncol.
44:393–402. 2014.
|
|
28
|
Tsai YP and Wu KJ: Hypoxia-regulated
target genes implicated in tumor metastasis. J Biomed Sci.
19:1022012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marín-Aguilera M, Codony-Servat J, Reig Ò,
Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P,
Mengual L, et al: Epithelial-to-mesenchymal transition mediates
docetaxel resistance and high risk of relapse in prostate cancer.
Mol Cancer Ther. 13:1270–1284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sui H, Zhu L, Deng W and Li Q:
Epithelial-mesenchymal transition and drug resistance: Role,
molecular mechanisms, and therapeutic strategies. Oncol Res Treat.
37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie J, Li DW, Chen XW, Wang F and Dong P:
Expression and significance of hypoxia-inducible factor-1α and
MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2
cells. Oncol Lett. 6:232–238. 2013.PubMed/NCBI
|
|
33
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Movafagh S, Crook S and Vo K: Regulation
of hypoxia-inducible factor-1α by reactive oxygen species: New
developments in an old debate. J Cell Biochem. 116:696–703. 2015.
View Article : Google Scholar
|
|
35
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
